- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00518310
Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study
Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease, associated with the histological appearance of usual interstitial pneumonia (UIP), with an inexorably deteriorating clinical course. Prognosis is poor, reported median survival is less than 3 years. The prevalence is estimated as being 3 to 10 per 100.000 in different Western populations. To date, no pharmacological therapy has been proven to alter or reverse the pathogenic process of IPF. Most treatments trials have been observational case series of small patient populations and very few have been randomized, prospective and placebo-controlled.
Two recent Cochrane reviews investigated the role of corticosteroids and other immunomodulatory agents and concluded that there is no evidence for their use in IPF. Most current therapies are targeted to suppress the inflammatory component of the disease, based on the theory that it would be chronic alveolar inflammation which leads to parenchymal remodeling and fibrosis. Recently, a hypothesis that has gained acceptance suggests that fibrosis may result directly from alveolar injury, promoting an abnormal fibrogenic repair mediated by fibroblasts and myofibroblasts.
One of the cytotoxic agents most widely used and better tolerated in the management of IPF is azathioprine. Based upon limited data available and from a single small high quality randomized controlled trial (RCT), this drug appears to confer, given in conjunction with prednisone, a marginal long term survival advantage. Since this combination therapy is associated serious adverse effect, we planned to design a trial of low dose corticosteroid and azathioprine versus placebo in management of IPF, evaluating progression-free survival.
Our study hypothesis is: Combined therapy with azathioprine and corticosteroids improves progression-free survival in patients with the diagnosis of IPF.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We will evaluate all adult patients consecutively referred from March 2005 to the Instituto Nacional del Tórax (Thorax National Institute), Santiago, Chile for diagnostic evaluation of Pulmonary Fibrosis. The routine evaluation will include, when indicated, the following steps:
- History:
- Age
- Genre
- Duration of symptoms before first consultation
- Smoking status
- Search for collagen vascular disease
- Family history of pulmonary fibrosis
- Occupational exposures
- Drug ot toxic exposures
- Physical examination: search of crackles and finger clubbing.
- Laboratory data:
- Complete blood bell count
- BUN
- Creatinine
- Liver enzymes
- Antinuclear antigens
- Erythrocyte sedimentation rate
- Rheumatoid factor
- HIV
- Antineutrophil cytoplasmic antibody (in appropiate clinical setting)
- Antiglomerular basement antibody (in appropiate clinical setting)
- Modified Medical Research Council Dyspnea Scale (MMRC) (10)
- Chronic Respiratory Questionnaire (CRQ) (11)
- Pulmonary function tests:
- Spirometry
- Plethismographic lung volumes
- DLco
- Composite physiologic index (12)
- Exercise testing:
- Six-Minute Walk Test (6MWT)
- Resting and 6 minute SpO2
- Presence or absence of desaturation to 88% or lower at the end of the six minute walk (13)
- Walked distance
- Pre and post modified Borg dyspnea scores
- Timed walk test (14)
- Arterial blood gas analysis in rest and exercise, calculating the difference between alveolar and arterial oxygen tension (P(A-a)O2) at rest and after exercise.
- Radiologic studies:
- Chest radiography
- HRCT:
Definite or probable idiopathic pulmonary fibrosis (15):
- Definitive criteria: presence of lung volume reduction, reticular abnormalities, traction bronchiectasis, or both, with a basal and peripheral predominance; the presence of honeycombing with a basal and peripheral predominance; and the absence of atypical features of usual interstitial pneumonia - micronodules, peribronchovascular nodules, consolidation, isolated (nonhoneycombing) cysts, ground-glass attenuation (or if present, less extensive than the reticular opacity), and mediastinal adenopathies (or if present, too limited to be visible on a chest radiography).
- Probable criteria: presence of a bilateral, predominantly basal and subpleural reticular pattern with subpleural cysts (honeycombing), traction bronchiectasis, or both in the absence of atypical features of UIP.
- Scoring of the extent of lung fibrosis (16).
- Bronchoscopy:
- Bronchoalveolar lavage: cellular analysis and CD4/CD8 ratio.
- Transbronchial biopsy.
- Surgical lung biopsy:
- Number
- Site/Side
- Type of surgery: open vs thoracoscopic
- Histologic features (3)
Those patients with IPF diagnosed on the basis of clinical and radiographic criteria alone according to the ATS/ERS consensus committee (3), and/or with a biopsy proven histological pattern of UIP, will be selected to the randomization process, after they have signed the written informed consent.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Matias Florenzano, MD
- Phone Number: 056 9 8294435
- Email: mflorenzano@terra.cl
Study Contact Backup
- Name: Alvaro Undurraga, MD
- Email: aundurragap@yahoo.com
Study Locations
-
-
RM
-
Santiago, RM, Chile
- Recruiting
- Instituto Nacional del tórax
-
Sub-Investigator:
- Jorge Navarro, MD
-
Contact:
- Jeannie Hinrichsen, RN
- Email: jhinrichsen@torax.cl
-
Contact:
- Carmen L Naranjo
- Email: cnaranjo@torax.cl
-
Principal Investigator:
- Florenzano Matias, MD
-
Principal Investigator:
- Undurraga Alvaro, MD
-
Sub-Investigator:
- Juan C Rodríguez, MD
-
Sub-Investigator:
- Carlos Inzunza, MD
-
Sub-Investigator:
- Mariam Torres, Ph
-
Sub-Investigator:
- Eduardo Sabbagh, MD
-
Sub-Investigator:
- Juan C Díaz, MD
-
Sub-Investigator:
- Gabriel Cavada, Stat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 45 and 79 years of age.
- Clinical symptoms of IPF for at least 3 months.
- Forced vital capacity (FVC) between 50 to 90% of the predicted value.
- DLco at least 35% of the predicted value.
- PaO2 > 55 mm Hg while breathing ambient air at rest.
- High-resolution computed tomography (HRCT) showing definite or probable criteria of IPF.
Exclusion Criteria:
- Clinically significant exposure to known fibrogenic agents (birds, molds, hot tubes, asbestos, radiation and drugs known to cause pulmonary fibrosis (amiodarone, nitrofurantoin, bleomicin,etc)).
- History of neurofibromatosis, Hermansky-Pudlak syndrome, metabolic storage disorders, etc.
- History of fever, weight loss, myalgias, arthralgias, skin rash, arthritis.
- Active infection within one week before enrollment.
- Alternative cause of interstitial lung disease.
- Ratio of the forced expiratory volume in one second (VEF1) to FVC of less than 0.6 after the use of a bronchodilator.
- Residual volume more than 120% of the predicted value (when available).
- More than 20% of lymphocytes or eosinophils in bronchoalveolar lavage (BAL) (when available).
- Granulomas, infection or malignancy in the transbronchial or surgical biopsy (when available).
- Previous therapy with azathioprine, prednisolone (>0.5 mg/kg/day or more for at least 3 months), cyclophosphamide or novel biotech drugs.
- Unstable cardiovascular or neurologic disease.
- Uncontrolled diabetes.
- Pregnancy.
- Lactation.
- Likelihood of death, as predicted by the investigator, within the next year.
- White cell blood count < 4000/mm3.
- Platelet count < 100000/mm3.
- Hematocrit < 30% or > 59%.
- Liver enzymes more than 3 times the upper limit of the normal range.
- Creatinine level > 1.5 mg/dL.
- Albumin level < 3 g/dL.
- Refusal to sign informed consent by patient or guardian.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator
Placebo
|
|
Active Comparator: 1
Azathiprine Prednisone
|
The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks.
The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day.
Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival, defined as free of death or a decrease from baseline in the FVC of at least 10%.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Acute Exacerbations of IPF.
Time Frame: 2 years
|
2 years
|
Health Related Quality of life, measured with the Chronic Questionnaire (CRQ).
Time Frame: 2 years
|
2 years
|
PO2 at rest and at exercise from baseline.
Time Frame: 2 years
|
2 years
|
P(A-a)O2 at rest and at exercise from baseline.
Time Frame: 2 years
|
2 years
|
Predicted FEV1 from baseline.
Time Frame: 2 years
|
2 years
|
Forced expiratory volume in one second (FEV1) to FVC from baseline.
Time Frame: 2 years
|
2 years
|
Plethysmographic lung volumes from baseline.
Time Frame: 2 years
|
2 years
|
Diffusion capacity for carbon monoxide (DLco) from baseline.
Time Frame: 2 years
|
2 years
|
Six-Minute Walk test, from baseline: resting and 6 minute SpO2, presence or absence of desaturation to 88% or lower at the end of the six minute walk, walked distance d. Pre and post modified Borg dyspnea scores
Time Frame: 2 years
|
2 years
|
Scoring of extent of lung fibrosis on HRCT, according to two independent chest radiologists, form baseline.
Time Frame: 2 years
|
2 years
|
Number and severity of adverse effects.
Time Frame: 2 years
|
2 years
|
Number of protocol drop outs.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Florenzano Matías, MD, Clinica Las Condes
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10351
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States